Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Daniel Petrylak
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
16
Hussain, Maha
8
Chatta, Gurkamal
8
Crawford, David
8
Small, Eric
7
Olsson, Carl
7
Benson, Mitchell
7
Higano, Celestia
6
Beer, Tomasz
6
Bagiella, E
5
Carducci, Michael
5
Eisenberger, Mario
5
Figg, William
5
Ryan, Christopher
5
Lara, Primo
4
Vaishampayan, Ulka Nitin
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Daniel Petrylak (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Sternberg Cora N; Petrylak Daniel P; Sartor Oliver; Witjes J Alfred; Demkow Tomasz; Ferrero Jean-Marc; Eymard Jean-Christophe; Falcon Silvia; Calabrò Fabio; James Nicholas; Bodrogi Istvan; Harper Peter; Wirth Manfred; Berry William; Petrone Michael E; McKearn Thomas J; Noursalehi Mojtaba; George Martine; Rozencweig Marcel
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5431-8.
-
2009: Hussain Maha; Goldman Bryan; Tangen Cathy; Higano Celestia S; Petrylak Daniel P; Wilding George; Akdas Atif M; Small Eric J; Donnelly Bryan J; Sundram Subramanian Kanaga; Burch Patrick A; Dipaola Robert S; Crawford E David
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(15):2450-6.
-
2009: Figg William D; Hussain Maha H; Gulley James L; Arlen Philip M; Aragon-Ching Jeanny B; Petrylak Daniel P; Higano Celestia S; Steinberg Seth M; Chatta Gurkamal S; Parnes Howard; Wright John J; Sartor Oliver; Dahut William L
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
The Journal of urology 2009;181(3):1104-13; discussion 1113.
-
2008: Smith David C; Mackler Niklas J; Dunn Rodney L; Hussain Maha; Wood David; Lee Cheryl T; Sanda Martin; Vaishampayan Ulka; Petrylak Daniel P; Quinn David I; Beekman Kathleen; Montie James E
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
The Journal of urology 2008;180(6):2384-8; discussion 2388.
-
2008: Gulley James L; Aragon-Ching Jeanny B; Steinberg Seth M; Hussain Maha H; Sartor Oliver; Higano Celestia S; Petrylak Daniel P; Chatta Gurkamal S; Arlen Philip M; Figg William D; Dahut William L
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
The Journal of urology 2008;180(4):1432-7; discussion 1437.
-
2008: Kalmadi Sujith R; Rankin Cathryn; Kraut Michael J; Jacobs Andrew D; Petrylak Daniel P; Adelstein David J; Keohan Mary Louise; Taub Robert N; Borden Ernest C
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
Lung cancer (Amsterdam, Netherlands) 2008;60(2):259-63.
-
2008: Beer Tomasz M; Goldman Bryan; Nichols Craig R; Petrylak Daniel P; Agarwal Manoj; Ryan Christopher W; Crawford E David;
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Clinical genitourinary cancer 2008;6(1):36-9.
-
2008: Lassiter Lance K; Tummala Mohan K; Hussain Maha H; Stadler Walter M; Petrylak Daniel P; Carducci Michael A
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
Clinical genitourinary cancer 2008;6(1):31-5.
-
2008: Scher Howard I; Halabi Susan; Tannock Ian; Morris Michael; Sternberg Cora N; Carducci Michael A; Eisenberger Mario A; Higano Celestia; Bubley Glenn J; Dreicer Robert; Petrylak Daniel; Kantoff Philip; Basch Ethan; Kelly William Kevin; Figg William D; Small Eric J; Beer Tomasz M; Wilding George; Martin Alison; Hussain Maha;
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1148-59.
-
2008: Mohile Supriya G; Schleicher Lori; Petrylak Daniel P
Treatment of metastatic urachal carcinoma in an elderly woman.
Nature clinical practice. Oncology 2008;5(1):55-8.
-
2008: Beer Tomasz M; Ryan Christopher W; Venner Peter M; Petrylak Daniel P; Chatta Gurkamal S; Ruether J Dean; Chi Kim N; Young James; Henner W David;
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Cancer 2008;112(2):326-30.
-
2007: Montgomery R Bruce; Goldman Bryan; Tangen Catherine M; Hussain Maha; Petrylak Daniel P; Page Stephanie; Klein Eric A; Crawford E David;
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
The Journal of urology 2007;178(5):1946-51; discussion 1951.
-
2007: Pierorazio Phillip M; McKiernan James M; McCann Tara R; Mohile Supriya; Petrylak Daniel; Benson Mitchell C
Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed.
BJU international 2007;100(4):755-9.
-
2007: Taylor Clare; Hershman Dawn; Shah Nina; Suciu-Foca Nicole; Petrylak Dan P; Taub Robert; Vahdat Linda; Cheng Bin; Pegram Mark; Knutson Keith L; Clynes Raphael
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5133-43.
-
2007: Boorjian Stephen A; Milowsky Matthew I; Kaplan Jodi; Albert Martin; Cobham Marta Vallee; Coll Deirdre M; Mongan Nigel P; Shelton Gary; Petrylak Daniel; Gudas Lorraine J; Nanus David M
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(6):655-62.
-
2007: Dinnen Richard D; Drew Lisa; Petrylak Daniel P; Mao Yuehua; Cassai Nicholas; Szmulewicz Joseph; Brandt-Rauf Paul; Fine Robert L
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance.
The Journal of biological chemistry 2007;282(37):26675-86.
-
2007: Hussain Maha H A; MacVicar Gary R; Petrylak Daniel P; Dunn Rodney L; Vaishampayan Ulka; Lara Primo N; Chatta Gurkamal S; Nanus David M; Glode L Michael; Trump Donald L; Chen Helen; Smith David C;
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2218-24.
-
2007: Kibel Adam S; Rosenbaum Eli; Kattan Michael W; Picus Joel; Dreicer Robert; Klein Eric A; Chatta Gurkamal S; Nelson Joel B; DiPaola Robert S; Roth Bruce J; Cookson Michael S; Wilding George; Jarrard David F; Beer Tomasz M; Ryan Christopher W; Petrylak Daniel P; Benson Mitchell C; Partin Alan W; Garrett-Mayer Elizabeth; Eisenberger Mario A
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
The Journal of urology 2007;177(5):1777-81.
-
2007: Petrylak Daniel P
Clinical trials in metastatic hormone-refractory prostate cancer: improving docetaxel therapy by targeting bone-related growth factors.
Current oncology reports 2007;9(3):211-2.
-
2007: Petrylak Daniel
Successive therapies may extend survival in AIPC. Interview by Alice Goodman.
RN 2007;70(3):1-2.
-
2007: Dreicer Robert; Petrylak Daniel; Agus David; Webb Iain; Roth Bruce
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1208-15.
-
2007: Beer Tomasz M; Ryan Christopher W; Venner Peter M; Petrylak Daniel P; Chatta Gurkamal S; Ruether J Dean; Redfern Charles H; Fehrenbacher Louis; Saleh Mansoor N; Waterhouse David M; Carducci Michael A; Vicario Daniel; Dreicer Robert; Higano Celestia S; Ahmann Frederick R; Chi Kim N; Henner W David; Arroyo Alan; Clow Fong W;
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):669-74.
-
2007: Mohile Supriya G; Bylow Kathryn; Dale William; Dignam James; Martin Kandis; Petrylak Daniel P; Stadler Walter M; Rodin Miriam
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
Cancer 2007;109(4):802-10.
-
2007: Petrylak Daniel P
New paradigms for advanced prostate cancer.
Reviews in urology 2007;9 Suppl 2():S3-S12.
-
2006: Lucas Aimee; Petrylak Daniel P
The case for early chemotherapy for the treatment of metastatic disease.
The Journal of urology 2006;176(6 Pt 2):S72-5.
-
2006: Beer Tomasz M; Venner Peter M; Ryan Christopher W; Petrylak Daniel P; Chatta Gurkamal; Dean Ruether J; Chi Kim N; Curd John G; DeLoughery Thomas G
High dose calcitriol may reduce thrombosis in cancer patients.
British journal of haematology 2006;135(3):392-4.
-
2006: Moss Rebecca A; Petrylak Daniel P
Cytotoxic chemotherapy for prostate cancer: Who and when?
Current treatment options in oncology 2006;7(5):370-7.
-
2006: McKiernan James M; Masson Puneet; Murphy Alana M; Goetzl Manlio; Olsson Carl A; Petrylak Daniel P; Desai Manisha; Benson Mitchell C
Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3075-80.
-
2006: Berry Donna L; Moinpour Carol M; Jiang Caroline S; Ankerst Donna Pauler; Petrylak Daniel P; Vinson Lynne V; Lara Primo N; Jones Sharon; Taplin Mary E; Burch Patrick A; Hussain Maha H A; Crawford E David
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2828-35.
-
2006: Mohile Supriya G; Petrylak Daniel P
Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer.
Current oncology reports 2006;8(3):213-20.
-
2006: Cella David; Petrylak Daniel P; Fishman Mayer; Teigland Chris; Young Jay; Mulani Parvez
Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
European urology 2006;49(5):781-9.
-
2006: Petrylak Daniel P; Ankerst Donna Pauler; Jiang Caroline S; Tangen Catherine M; Hussain Maha H A; Lara Primo N; Jones Jeffrey A; Taplin Mary Ellen; Burch Patrick A; Kohli Manish; Benson Mitchell C; Small Eric J; Raghavan Derek; Crawford E David
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Journal of the National Cancer Institute 2006;98(8):516-21.
-
2006: Sonpavde Guru; Petrylak Daniel P
Perioperative chemotherapy for bladder cancer.
Critical reviews in oncology/hematology 2006;57(2):133-44.
-
2006: McClelland Shearwood; Garcia Rebeca E; Monaco Sara E; Goldman James E; Olson Ty J; Kim Grace H; Petrylak Daniel P; Goodman Robert R
Carcinomatous meningitis from urachal carcinoma: the first reported case.
Journal of neuro-oncology 2006;76(2):171-4.
-
2006: Petrylak Daniel P
The treatment of hormone-refractory prostate cancer: docetaxel and beyond.
Reviews in urology 2006;8 Suppl 2():S48-55.
-
2005: Petrylak Daniel
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
BJU international 2005;96 Suppl 2():41-6.
-
2005: Hussain Maha; Tangen Catherine M; Lara Primo N; Vaishampayan Ulka N; Petrylak Daniel P; Colevas A Dimitrios; Sakr Wael A; Crawford E David;
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8724-9.
-
2005: Vaishampayan Ulka N; Faulkner James R; Small Eric J; Redman Bruce G; Keiser Wayne L; Petrylak Daniel P; Crawford E David
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Cancer 2005;104(8):1627-32.
-
2005: Petrylak Daniel P
Future directions in the treatment of androgen-independent prostate cancer.
Urology 2005;65(6 Suppl):8-12.
-
2005: Petrylak Daniel P
The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Urology 2005;65(5 Suppl):3-7; discussion 7-8.
-
2005: Donohue Kathleen M; Petrylak Daniel P
Chemotherapy agents and timing of chemotherapy in prostate cancer management.
Current urology reports 2005;6(3):224-7.
-
2005: Chen Allen C; Petrylak Daniel P
Complications of androgen-deprivation therapy in men with prostate cancer.
Current urology reports 2005;6(3):210-6.
-
2005: Boyar Michelle; Petrylak Daniel P
Adjuvant chemotherapy for transitional cell carcinoma of the bladder: paradigms for the design of clinical trials.
Current oncology reports 2005;7(3):207-14.
-
2005: Petrylak Daniel P
Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit.
Current oncology reports 2005;7(3):205-6.
-
2005: Gulley James L; Figg William D; Steinberg Seth M; Carter Jane; Sartor Oliver; Higano Celestia S; Petrylak Daniel P; Chatta Gerkamal; Hussain Maha H; Dahut William L
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
The Journal of urology 2005;173(5):1567-71.
-
2005: Bhandari Manish S; Petrylak Daniel P; Hussain Maha
Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
European journal of cancer (Oxford, England : 1990) 2005;41(6):941-53.
-
2005: Petrylak Daniel P
Chemotherapy for androgen-independent prostate cancer.
World journal of urology 2005;23(1):10-3.
-
2004: Ahles Tim A; Herndon James E; Small Eric J; Vogelzang Nicholas J; Kornblith Alice B; Ratain Mark J; Stadler Walter; Palchak David; Marshall M Ernest; Wilding George; Petrylak Daniel; Holland Jimmie C;
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Cancer 2004;101(10):2202-8.
-
2004: Petrylak Daniel P; Tangen Catherine M; Hussain Maha H A; Lara Primo N; Jones Jeffrey A; Taplin Mary Ellen; Burch Patrick A; Berry Donna; Moinpour Carol; Kohli Manish; Benson Mitchell C; Small Eric J; Raghavan Derek; Crawford E David
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
The New England journal of medicine 2004;351(15):1513-20.
-
2004: Chen Allen C; Petrylak Daniel P
Complications of androgen deprivation therapy in men with prostate cancer.
Current oncology reports 2004;6(3):209-15.
-
2004: Scher Howard I; Eisenberger Mario; D'Amico Anthony V; Halabi Susan; Small Eric J; Morris Michael; Kattan Michael W; Roach Mack; Kantoff Philip; Pienta Kenneth J; Carducci Michael A; Agus David; Slovin Susan F; Heller Glenn; Kelly William Kevin; Lange Paul H; Petrylak Daniel; Berg William; Higano Celestra; Wilding George; Moul Judd W; Partin Alan N; Logothetis Christopher; Soule Howard R
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):537-56.
-
2004: Neugut Alfred I; Chen Allen C; Petrylak Daniel P
The "skinny" on obesity and prostate cancer prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):395-8.
-
2003: Syed Samira; Petrylak Daniel P; Thompson Ian M
Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches.
Urologic oncology 2003;21(3):235-43.
-
2003: Petrylak Daniel P
Early chemohormonal therapy in prostate cancer: preliminary data and randomized trials.
Current oncology reports 2003;5(3):229-30.
-
2003: Crawford E David; Wood David P; Petrylak Daniel P; Scott Jennifer; Coltman Charles A; Raghavan Derek;
Southwest Oncology Group studies in bladder cancer.
Cancer 2003;97(8 Suppl):2099-108.
-
2003: Li Yin; Raffo Anthony J; Drew Lisa; Mao Yuehua; Tran Andy; Petrylak Daniel P; Fine Robert L
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Cancer research 2003;63(7):1527-33.
-
2003: Do Tamara N; Rosal Ramon V; Drew Lisa; Raffo Anthony J; Michl Josef; Pincus Matthew R; Friedman Fred K; Petrylak Daniel P; Cassai Nicholas; Szmulewicz Joseph; Sidhu Gurdip; Fine Robert L; Brandt-Rauf Paul W
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
Oncogene 2003;22(10):1431-44.
-
2003: Tiersten Amy D; Nelsen Caron; Talbot Susan; Vahdat Linda; Fine Robert; Troxel Andrea; Brafman Lois; Shriberg Laureen; Antman Karen; Petrylak Daniel P
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Cancer 2003;97(3):537-44.
-
2003: Petrylak Daniel P
Docetaxel for the treatment of hormone-refractory prostate cancer.
Reviews in urology 2003;5 Suppl 2():S14-21.
-
2003: Petrylak Daniel P
Hormone-refractory prostate cancer: new horizons.
Reviews in urology 2003;5 Suppl 6():S54-8.
-
2003: Petrylak Daniel P
Docetaxel for the treatment of hormone-refractory prostate cancer.
Reviews in urology 2003;5 Suppl 3():S14-21.
-
2002: Drew Lisa; Fine Robert L; Do Tamara N; Douglas Geoffrey P; Petrylak Daniel P
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3922-32.
-
2002: Goldberg Jonathan S; Vargas Manuel; Rosmarin Alyssa S; Milowsky Matthew I; Papanicoloau Nicholas; Gudas Lorraine J; Shelton Gary; Feit Kevie; Petrylak Daniel; Nanus David M
Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.
Cancer 2002;95(6):1220-7.
-
2002: Petrylak Daniel P
Chemotherapy for androgen-independent prostate cancer.
Seminars in urologic oncology 2002;20(3 Suppl 1):31-5.
-
2002: Petrylak Daniel P; de Wit Ronald
Editorial: the coming revolution in the treatment of prostate cancer patients.
Seminars in urologic oncology 2002;20(3 Suppl 1):1-3.
-
2002: Small Eric J; Halabi Susan; Ratain Mark J; Rosner Gary; Stadler Walter; Palchak David; Marshall Ernest; Rago Randall; Hars Vera; Wilding George; Petrylak Daniel; Vogelzang Nicholas J
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3369-75.
-
2002: Petrylak Daniel P
Salvage therapy for platinum-refractory urothelial cancer: designing new clinical trials.
Cancer investigation 2002;20(5-6):855-6.
-
2000: Lee N; Fawaaz R; Olsson C A; Benson M C; Petrylak D P; Schiff P B; Bagiella E; Singh A; Ennis R D
Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients.
International journal of radiation oncology, biology, physics 2000;48(5):1443-6.
-
2000: Small E J; Lew D; Redman B G; Petrylak D P; Hammond N; Gross H M; Eastham J A; Crawford E D
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(13):2537-44.
-
2000: Kline R P; Wu E X; Petrylak D P; Szabolcs M; Alderson P O; Weisfeldt M L; Cannon P; Katz J
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2146-56.
-
2000: Ennis R D; Petrylak D P; Singh P; Bagiella E; O'Toole K M; Benson M C; Olsson C A
The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
The Journal of urology 2000;163(5):1413-8.
-
2000: Petrylak D P
Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Seminars in oncology 2000;27(2 Suppl 3):24-9.
-
2000: Hussain M; Fisher E I; Petrylak D P; O'Connor J; Wood D P; Small E J; Eisenberger M A; Crawford E D
Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1043-9.
-
2000: Weitzman A L; Shelton G; Zuech N; Owen C E; Judge T; Benson M; Sawczuk I; Katz A; Olsson C A; Bagiella E; Pfaff C; Newhouse J H; Petrylak D P
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
The Journal of urology 2000;163(3):834-7.
-
1999: Bubley G J; Carducci M; Dahut W; Dawson N; Daliani D; Eisenberger M; Figg W D; Freidlin B; Halabi S; Hudes G; Hussain M; Kaplan R; Myers C; Oh W; Petrylak D P; Reed E; Roth B; Sartor O; Scher H; Simons J; Sinibaldi V; Small E J; Smith M R; Trump D L; Wilding G
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3461-7.
-
1999: Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Seminars in oncology 1999;26(5 Suppl 17):55-60.
-
1999: Petrylak D P; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
Seminars in oncology 1999;26(5 Suppl 17):28-33.
-
1999: Lee N; Newhouse J H; Olsson C A; Benson M C; Petrylak D P; Schiff P B; Bagiella E; Malyszko B; Ennis R D
Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients.
Urology 1999;54(3):490-4.
-
1999: Petrylak D P; Macarthur R B; O'Connor J; Shelton G; Judge T; Balog J; Pfaff C; Bagiella E; Heitjan D; Fine R; Zuech N; Sawczuk I; Benson M; Olsson C A
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):958-67.
-
1995: Khaled Z; Rideout D; O'Driscoll K R; Petrylak D; Cacace A; Patel R; Chiang L C; Rotenberg S; Stein C A
Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(1):113-22.
-
1994: Petrylak D P; Yagoda A; O'Toole K M; Chadburn A; Sawczuk I S; Benson M C; Olsson C A; Allegretta L; Saad A D; Wartinger D D
Transferrin receptor expression in testis cancer.
Journal of the National Cancer Institute 1994;86(8):636-7.
Sign-in to see more
